Ikarian Capital’s Acadia Pharmaceuticals ACAD Stock Holding History

Ikarian Capital’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$711K	Hold	28,099	–	–	0.08%	116
2026 Q1	$625K	Buy	+28,099	New	+$672K	0.05%	122
2023 Q2	–	Sell	-60,000	Closed	-$1.13M	–	123
2023 Q1	$1.13M	Sell	60,000 -265,000	-82%	-$5.05M	0.26%	72
2022 Q4	$5.17M	Hold	325,000	–	–	1.25%	28
2022 Q3	$5.32M	Buy	+325,000	New	+$5.26M	1.06%	34
2022 Q2	–	Sell	-1,882	Closed	-$46K	–	138
2022 Q1	$46K	Buy	1,882 +117	+7%	+$2.83K	0.01%	185
2021 Q4	$42K	Sell	1,765 -280,000	-99%	-$5.63M	0.01%	175
2021 Q3	$4.68M	Buy	281,765 +71,899	+34%	+$1.39M	0.33%	70
2021 Q2	$5.12M	Buy	209,866 +203,858	+3,393%	+$4.6M	0.41%	68
2021 Q1	$155K	Sell	6,008 -50,000	-89%	-$2.2M	0.01%	275
2020 Q4	$3M	Hold	56,008	–	–	0.13%	132
2020 Q3	$2.31M	Buy	56,008 +10,000	+22%	+$432K	0.17%	108
2020 Q2	$2.23M	Buy	+46,008	New	+$2.21M	0.18%	103

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Ikarian Capital's ACAD Position: Q2 2026 in Review

Ikarian Capital held its Acadia Pharmaceuticals (ACAD) position steady in Q2 2026 at 28,099 shares worth $711K. The position accounts for 0.08% of the portfolio, ranked #116.

Ikarian Capital first reported a position in ACAD in Q2 2020 and has held it in 13 quarters since. The position peaked at $5.32M in Q3 2022. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

Ikarian Capital held 28,099 shares of Acadia Pharmaceuticals worth $711K as of Q2 2026.
Ikarian Capital left its Acadia Pharmaceuticals share count unchanged in Q2 2026.
Acadia Pharmaceuticals made up 0.08% of Ikarian Capital's portfolio in Q2 2026, its #116 holding.
Ikarian Capital first reported a position in Acadia Pharmaceuticals in Q2 2020 and has held it in 13 quarters since.
Ikarian Capital's Acadia Pharmaceuticals position peaked at $5.32M in Q3 2022.
354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.